58 results on '"Krenning, Eric"'
Search Results
2. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
3. 99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice
4. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer
5. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
6. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands
7. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
8. [DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1–5 profile, stability and tumor targeting
9. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
10. 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives
11. Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
12. Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides
13. Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy
14. Biodistribution of [111In-DOTA0,trp8]SS-14 in sst2/3/5+-HEK tumor-bearing mice
15. [(111In-DOTA)Lys0]Tate: effects of Lys0-Introduction on AR4-2J tumor and kidney uptake in SCID mice
16. Comparison of [111In]SAR-G2 and 3 in GRPR+ cells and animal models
17. Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
18. Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
19. Peak bone mineral density, lean body mass and fractures
20. Gastroenteropancreatic neuroendocrine tumours
21. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences
22. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys
23. Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues
24. The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation
25. Peptide receptor radionuclide therapy
26. Anaphylactoid reaction from amifostine
27. Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
28. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs
29. Prognostic Implications of a Normal Stress Technetium-99m–Tetrofosmin Myocardial Perfusion Study in Patients With a Healed Myocardial Infarct and/or Previous Coronary Revascularization
30. Peptide receptor radionuclide therapy
31. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
32. Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests
33. Relation between QT dispersion and myocardial viability in ischemic cardiomyopathy
34. Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting
35. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia
36. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
37. Somatostatin receptor imaging
38. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
39. Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis
40. Safety, Hemodynamic Profile, and Feasibility of Dobutamine Stress Technetium Myocardial Perfusion Single-Photon Emission CT Imaging for Evaluation of Coronary Artery Disease in the Elderly
41. Therapeutic use of radiolabelled peptides
42. Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction
43. Identification of Thyroid Hormone Transporters
44. 99mTc-MIBI, 99mTc-Tetrofosmin and 99mTc-Q12 In Vitro and In Vivo
45. Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats
46. D-lysine for reduction of renal[in-111-DTPA,D-phe-1 ]-octreotide and [Y-90-DOTA,D-phe-1,tyr-3]octreotide uptake
47. Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain
48. Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction
49. 772-2 Local Intracoronary Delivery of Heparin and of a Somatostatin Analogue (Octreotide) Following Angioplasty in Man: Evaluation of Efficacy of Delivery by Radio-Isotopic Technique
50. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.